Latest From Biocon Ltd.
With one high-profile approval in its pocket – a version of Teva's blockbuster Copaxone – Mylan's management believes its strategy of investing in complex generics and biosimilars will help the company navigate challenges in the US generic market.
USV Ltd expects to progress studies with Diabetology’s oral insulin in India, five years after the companies signed a licensing deal in 2012. The oral insulins space has seen mixed progress in the recent past, with a high profile pullback and funding support in another instance for an oral insulin candidate.
The EMA’s scientific committee, the CHMP, now has four biosimilar versions of Amgen’s neutropenia drug Neulasta (pegfilgrastim) under review, after Sandoz re-submitted its product at the end of October.
Sponsors shouldn't wait until pre-submission meetings with the agency to discuss manufacturing, packaging and other matters unrelated to similarity data, FDA's Leah Christl says in remarks seemingly aimed at calling attention to issues that can forestall approval.
- Large Molecule
- Medical Devices
- Therapeutic Areas
- Parent & Subsidiaries
- Biocon Ltd.
- Senior Management
Arun ` Chandavarkar, PhD, CEO
Siddharth Mittal, CFO
Ravi Limay, Pres., Mktg.
Narendra Chirmule, PhD, SVP & Head, R&D
- Contact Info
Phone: (91) 80 2808 2808
20th KM Hosur Rd.
Bangalore , 560 100
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.